References | Author, year | Number of patients | Blood samples | Planar imaging | SPECT/CT imaging | Activity modeling | Bone marrow dosimetry | S factor | Bone marrow absorbed dose (Gy/GBq) |
---|---|---|---|---|---|---|---|---|---|
[12] | Kwekkeboom, 2001 | 5 | 10, 20, 40, 60 and 90 min and 2, 5 and 24 h p.i | 4 h, and 1, 3, 10, 17 days p.i | – | – | Planar | – | 0.07 |
[13] | Wehrmann, 2007 | 27 | 3, 10, 20,40 min and 1, 2, 4, 6, 20, 32, 44, 66, 70 h p.i | – | – | Bi or tri exponential | Blood | OLINDA | 0.04 ± 0.02 |
[9] | Forrer, 2009 | 15 | 5 samples between 0 and 168 h p.i | 3 images between 24 and 168 h p.i | – | – | Blood + planar | OLINDA | 0.034 ± 0.03 |
[2] | Bodei, 2011 | 12 | – | – | – | – | – | – | 0.033 |
[14] | Jackson, 2013 | 17 | – | – | 4, 24 72 h p.i | Tri exponential | SPECT/CT | Monte-Carlo simulations | 0.0334 ± 0.012 |
[15] | Sandström, 2013 | 200 | 0.5, 1, 2.5,4,8, 24 h p.i | 24, 96, 168 h p.i | 24, 96, 168 h p.i | Mono exponential | Blood + planar | RADAR | 0.007—0.054 |
[4] | Bodei, 2015 | 10 | – | – | – | – | – | – | 0.03 |
[16] | Denoyer, 2015 | 11 | – | – | 4, 24, 72h p.i | – | SPECT/CT | OLINDA | 0.0315 |
[17] | Bergsma, 2016 | 24 | 0,10,30,60,90,120, 360 1440 min p.i | 24, 96, 168 h p.i | – | – | Blood + planar | OLINDA | 0.067 ± 0.007 |
[18] | Svensson, 2016 | 46 | – | 2, 24, 48 168 h p.i | 24 h p.i | Bi-exponential | Planar | RADAR | 0.027 ± 0.007 |
[19] | Del Prete, 2017 | 22 | – | – | 4, 24 72 h p.i | Mono exponential | SPECT/CT | OLINDA | 0.046 ± 0.033 |
[20] | Gosewich, 2018 | 5 | 30, 80 min and 24,48, 72 h p.i | 24, 48, 72 h p.i | 24, 48, 72 h p.i | Mono and bi exponential | Blood + SPECT/CT | RADAR | 0.012 ± 0.003 |
[21] | Del Prete, 2019 | 34 | – | – | 4, 24 72 h p.i | Linear + mono exponential | SPECT/CT | OLINDA | 0.035 |
[22] | Santoro, 2018 | 12 | – | – | 4, 24, 72 192 h p.i | Mono exponential | SPECT/CT | OLINDA | 0.04 ± 0.02 |
[23] | Marin, 2018 | 47 | 30 min, 1, 4, 24 and 144–192 h p.i | – | 4, 24, 144–192 h p.i | Bi-exponential | Blood + SPECT/CT | OLINDA | 0.028 ± 0.01 |
[24] | Thakral, 2018 | 10 | – | 2, 24, 96 h p.i | – | Mono/bi exponential | Planar | OLINDA | 0.017 ± 0.016 |
[25] | Chicheportiche, 2018 | 24 | 18, 20—25 h p.i | – | 18, 25 h and 7 d p.i | Mono exponential | Blood + SPECT/CT | OLINDA | 0.0096 |
[8] | Garske-Roman, 2018 | 200 | 0.5, 1, 2.5, 4, 8, 24 h p.i | 1, 4, 7 d p.i | 1, 4, 7 d p.i | Mono exponential | Blood + planar | - | 0.018 |
[7] | Hagmarker, 2019 | 46 | – | 2, 24, 48, 168 h p.i | 24 h p.i | Mono/bi-exponential | Planar + SPECT/CT | ICRP 133 | 0.016–0.287 |
[26] | Hallqvist, 2021 | 17 | – | 2, 24, 48, 168 h p.i | 24 h p.i | Mono/bi-exponential | Planar + SPECT/CT | – | 0.041 |
[27] | Carter, 2021 | 2 | – | – | – | – | SPECT/CT | ICRP, Monte-Carlo simulations | 0.043–0.13 |
[28] | Vergnaud, 2022 | 13 | – | – | 1, 24, 96 or 144 h p.i | Tri-exponential | SPECT/CT | Monte-Carlo simulations | 0.04 ± 0.02 |